Benjamin F. Edwards & Company, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 356 shares of ALNY stock, worth $162,350. This represents 0.0% of its overall portfolio holdings.
Number of Shares
356
Previous 404
11.88%
Holding current value
$162,350
Previous $60,000
45.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ALNY
# of Institutions
808Shares Held
115MCall Options Held
584KPut Options Held
648K-
Capital World Investors Los Angeles, CA16.8MShares$7.66 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$6.06 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.35 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.28 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$1.95 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $56.1B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...